AU2002308169A1 - Compositions and methods for reducing rna virus pathogenicity - Google Patents

Compositions and methods for reducing rna virus pathogenicity

Info

Publication number
AU2002308169A1
AU2002308169A1 AU2002308169A AU2002308169A AU2002308169A1 AU 2002308169 A1 AU2002308169 A1 AU 2002308169A1 AU 2002308169 A AU2002308169 A AU 2002308169A AU 2002308169 A AU2002308169 A AU 2002308169A AU 2002308169 A1 AU2002308169 A1 AU 2002308169A1
Authority
AU
Australia
Prior art keywords
compositions
methods
rna virus
virus pathogenicity
reducing rna
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002308169A
Other languages
English (en)
Inventor
Melinda Beck
Bruce German
Orville Levander
Peter Van Dael
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Societe des Produits Nestle SA
University of North Carolina at Chapel Hill
Original Assignee
Societe des Produits Nestle SA
Nestle SA
University of North Carolina at Chapel Hill
University of North Carolina System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Societe des Produits Nestle SA, Nestle SA, University of North Carolina at Chapel Hill, University of North Carolina System filed Critical Societe des Produits Nestle SA
Publication of AU2002308169A1 publication Critical patent/AU2002308169A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/04Sulfur, selenium or tellurium; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/145Orthomyxoviridae, e.g. influenza virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011Details
    • C12N2760/16011Orthomyxoviridae
    • C12N2760/16111Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2002308169A 2001-03-28 2002-03-26 Compositions and methods for reducing rna virus pathogenicity Abandoned AU2002308169A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US81938701A 2001-03-28 2001-03-28
US09/819,387 2001-03-28
PCT/EP2002/003025 WO2002078717A2 (fr) 2001-03-28 2002-03-26 Compositions et methodes pour reduire la pathogenicite de virus a arn

Publications (1)

Publication Number Publication Date
AU2002308169A1 true AU2002308169A1 (en) 2002-10-15

Family

ID=25228011

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002308169A Abandoned AU2002308169A1 (en) 2001-03-28 2002-03-26 Compositions and methods for reducing rna virus pathogenicity

Country Status (2)

Country Link
AU (1) AU2002308169A1 (fr)
WO (1) WO2002078717A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111568921A (zh) * 2020-04-20 2020-08-25 奥格生物技术(六安)有限公司 一种促进冠状病毒患者康复的新型硒制剂配方及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2089607C (fr) * 1992-11-05 1997-11-04 Ranjit K. Chandra Supplement nutritionnel pour personnes agees
EP1007077B1 (fr) * 1997-01-13 2009-10-07 Emory University Glutathione destines au traitement de l'infection grippale
US5770217A (en) * 1997-07-02 1998-06-23 Atlatl, Inc. Dietary supplement for hematological, immune and appetite enhancement

Also Published As

Publication number Publication date
WO2002078717A2 (fr) 2002-10-10
WO2002078717A3 (fr) 2003-08-28

Similar Documents

Publication Publication Date Title
EP1292603B8 (fr) Methodes et compositions permettant de traiter le virus de l'hepatite c
AU2002357119A1 (en) Mitocidal compositions and methods
EP1420829A4 (fr) Compositions immunomodulatrices, preparations, et leurs procedes d'utilisation
AU2001245437A1 (en) Lightweight methods and compositions for well treating
AU2003254594A1 (en) Methods and compositions for detecting sars virus and other infectious agents
AU2002363236A1 (en) Compounds, pharmaceutical compositions and methods of use therefor
AU2001280968A1 (en) Compositions and methods for directed gene assembly
AU2003239129A1 (en) Methods and compositions for dna manipulation
AU2001253255A1 (en) Compositions and methods for inhibiting gene expression
AU2001245987A1 (en) Compositions and methods for gene therapy
AU2002346686A1 (en) Compositions and method for treating hepatitis virus infection
AU2001275155A1 (en) Superoxide-generating diazeniumdiolates, compositions comprising same, and methods for using same
AU2003286486A1 (en) Methods and compositions for immunization against hiv
AU2002306968A1 (en) Ogri gene disruptions, compositions and methods relating thereto
AU2002357748A1 (en) Osteopontin-related compositions and methods
AU2003294757A1 (en) Formulations useful against hepatitis c virus infections
AU2002306709A1 (en) Oncolytic rna replicons
AU2002324753A1 (en) Composition and method for treating viral infection
AU2002345878A1 (en) Ilt3 and ilt4-related compositions and methods
AU2002353780A1 (en) Mo54 gene disruptions, compositions and methods related thereto
AU2002365442A1 (en) Method of inhibiting pathogenicity of infectious agents
AU2002316512A1 (en) Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes
AU2756301A (en) Compositions comprising genome segments and methods of using the same
AU2003275069A1 (en) Compositions and methods for preventing infection
AU2003303948A1 (en) Compositions and methods for preventing infection

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase